#TeamKura is proud to join the The Leukemia & Lymphoma Society for our 4th consecutive #LighttheNight event! Together, we're bringing light to the darkness of cancer by supporting groundbreaking research and bringing hope to patients and families battling blood cancers. Join us as we walk to celebrate, honor, and remember those affected. Find a Light the Night walk near you and help shine a light in the fight against blood cancer! https://lnkd.in/dFqbRn8 #LLSUSA
Kura Oncology, Inc.
Biotechnology Research
San Diego, California 21,322 followers
Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives.
About us
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.
- Website
-
http://www.kuraoncology.com
External link for Kura Oncology, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2014
- Specialties
- Oncology, Precision Medicine, Targeted Therapeutics, Biomarkers, Solid Tumors, Blood Cancers, and Research and Development
Locations
-
Primary
12730 High Bluff Dr
Suite 400
San Diego, California 92130, US
-
2 Seaport Ln
Suite 8A
Boston, Massachusetts 02210, US
Employees at Kura Oncology, Inc.
Updates
-
At Kura, we believe in cultivating an environment where every voice is heard, nurtured, and valued. This #GlobalDiversityAwarenessMonth, we’re honored to highlight our ongoing partnership with Life Science Cares San Diego and Life Science Cares Boston. Through our mutual collaboration, we provide underrepresented students the tools and experiences to pursue a career in #STEM. By removing barriers and creating growth opportunities, we’re hoping to build a more diverse workforce that will drive the next wave of scientific breakthroughs. Thank you to Life Science Cares for your continued efforts to build equity and inclusion for all! #GlobalDiversityAwarenessMonth
-
Data from our KOMET-001 Phase 1 study has been published in The Lancet Oncology journal! Learn more about the clinical data and what it means for ziftomenib’s potential in relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (#AML): https://bit.ly/3XFaYO8
-
On #RareCancerDay, September 30, join Kura Oncology in showing support for patients, clinicians, and scientists fighting rare cancers. Despite >500 types of rare cancers, fewer than 40,000 people are affected annually. With fewer patients, rare cancers can be hard to study, treat, and cure. Through its ongoing clinical trial programs, Kura Oncology is exploring new therapies designed to address rare cancer challenges. Learn about our clinical trial programs in head and neck cancer, lung cancer, and acute leukemias: https://bit.ly/4earkWd
-
Our Chief Commercial Officer, Brian Powl, will join a panel discussion around best practices for effective drug launch planning at the 2024 Fierce New Product Planning Summit in Boston next week. Here, he will share his insights from his experience across pharma and biotechnology companies. Learn more: https://sched.co/1ehzT Fierce Life Sciences Events | #FierceNPP
-
For the second year in a row, we are #ScripAwards finalists! Thank you to our partners and everyone at #TeamKura for your work in securing two finalist slots, including: Executive of the Year for our President and CEO, Troy Wilson, Ph.D., J.D. and Community Partnership of the Year for our ongoing collaboration with Life Science Cares San Diego and Life Science Cares Boston. See the full shortlist of Citeline’s 2024 Scrip Awards here and stay tuned as the winners are announced.: https://bit.ly/3Bb1mDz
-
Today, on #WorldCancerResearchDay, we join our broader community in advancing the growing body of research to understand and treat #cancer. We are deeply grateful to the researchers, clinicians, industry professionals and patient community who make daily progress in our collective understanding of cancer. Your relentless passion and pursuit of innovation are at the heart of every breakthrough we make. Together, let’s continue to push the boundaries and make a lasting impact in the #oncology space for the benefit of patients and their loved ones. Learn more about our approach to advance potential cancer treatments: https://lnkd.in/gbCpE5mm
-
With major milestones met in the KOMET clinical trial program exploring ziftomenib, an investigational menin inhibitor, Kura Oncology has made monumental progress toward our goal of realizing the potential of precision medicine in acute leukemias. There is much more to discover about the potential impact of ziftomenib on the standard of care for patients with NPM1-m or KMT2A-r AML. Discover more on the KOMET clinical trial program and ziftomenib: https://bit.ly/3WafkMP
-
Kura Oncology, Inc. reposted this
The LLS #LightTheNight season is so close – we can feel it! ✨ Help us bring light to the darkness of cancer this fall by registering for an event near you 👉 https://bit.ly/4dHDJkd
-
+3
-
On the heels of #TeamKura being recognized in Fast Company’s Best Workplaces for Innovators list, our COO Kathy Ford expresses her gratefulness for our team in her LinkedIn article. Read more to hear her thoughts on the importance of fostering a workplace fit for #innovators to thrive and work together as one for #cancer patients.